$0 – $10

QB3 Seminar: Sofie Qiao, Vivace Therapeutics: Tackling Novel Drug Targets a...

Event Information

Share this event

Date and Time

Location

Location

Room N-114, Genentech Hall

600 16th St.

UCSF Mission Bay

San Francisco, CA 94158

View Map

Event description

Description

Creating a virtual startup is an option for a seasoned pharma scientist who wants to develop drugs on a lean budget. In the past this has only been feasible when going after a known target. Now, however, improved CRO capabilities in biology make it possible to launch a company that explores the science of a pathway while simultaneously developing drugs to target that pathway. A prime example of such a company is Vivace Therapeutics, co-founded and led by Sofie Qiao. Interested in hearing Vivace's story? Join us on February 7.

About the Speaker

Sofie Qiao

Dr. Qiao is the founding president and CEO of Vivace Therapeutics, and a member of the board of directors. Prior to co-founding Vivace, she served as managing director of WuXi ventures, the corporate venture arm of WuXi AppTec. Dr. Qiao co-founded the chemistry-driven drug discovery company LEAD Therapeutics in 2006, assembled the management team and played a central role in raising $17 million in Series A financing. The company was acquired in 2010 by BioMarin for up to $97 million, primarily for its PARP inhibitor (Talazoparib), then in preclinical development. Dr. Qiao began her industry career at Genzyme as a medicinal chemist, and later moved into business roles with McKinsey & Company, Syrrx (now Takeda California) and Discovery Partners International (now Galapagos). She holds a doctorate in organic chemistry from Massachusetts Institute of Technology and an A.B. in chemistry from Harvard University.

Share with friends

Date and Time

Location

Room N-114, Genentech Hall

600 16th St.

UCSF Mission Bay

San Francisco, CA 94158

View Map

Save This Event

Event Saved